TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29851569

Group type: EXPERIMENTAL
Intervention: NAP (afternoon nap approximately 90 minutes before evening exercise)
Number of subjects: 11

Group type: COMPARATOR
Intervention: CON (no afternoon nap)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: NAP
Number of subjects: 11
Study: 27256922

Group type: EXPERIMENTAL
Intervention: MK‐1064 (OX2R antagonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dual orexin receptor antagonists (for comparison)
Number of subjects: 0
Study: 25614171

Group type: EXPERIMENTAL
Intervention: 3-month prednisolone treatment (0.5 mg·kg(‐1)·day(‐1) for 3 months, then tapered)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 6-month prednisolone treatment (0.5 mg·kg(‐1)·day(‐1) for 6 months, then tapered)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Both treatment groups (3-month and 6-month prednisolone)
Number of subjects: 44
Study: 23165467

Group type: EXPERIMENTAL
Intervention: Enfuvirtide (ENF) for 24 weeks
Number of subjects: 195

Group type: COMPARATOR
Intervention: Control (no enfuvirtide)
Number of subjects: 195
Study: 20595110

Group type: EXPERIMENTAL
Intervention: CPCS stem
Number of subjects: 34

Group type: COMPARATOR
Intervention: Exeter stem
Number of subjects: 34
Study: 19056708

Group type: EXPERIMENTAL
Intervention: Newer antiretroviral therapies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Earlier antiretroviral therapies
Number of subjects: 0
Study: 16630150

Group type: EXPERIMENTAL
Intervention: RWJ-58643 (100 microg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Budesonide (200 microg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: RWJ-58643 (300 microg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: RWJ-58643 (600 microg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 12751980

Group type: EXPERIMENTAL
Intervention: Educational programmes for bartenders (n = 40) in intervention pubs
Number of subjects: 1322

Group type: COMPARATOR
Intervention: Control pubs (no educational programme)
Number of subjects: 1322
Study: 10769553

Group type: EXPERIMENTAL
Intervention: EMLA cream (1 g)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Placebo cream (1 g)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Mepivacaine infiltration (0.2 ml of 1%)
Number of subjects: 153
Study: 9314631

Group type: EXPERIMENTAL
Intervention: Insulin lispro in combination with sulfonylureas
Number of subjects: 25

Group type: COMPARATOR
Intervention: Sulfonylureas alone
Number of subjects: 25
Study: 8349803

Group type: EXPERIMENTAL
Intervention: Grass pollen immunotherapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 3713148

Group type: EXPERIMENTAL
Intervention: Novel automated visual field testing instrument
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional automatic tests
Number of subjects: 0
Study: 29858713

Group type: EXPERIMENTAL
Intervention: COMPASS intervention
Number of subjects: 0
Study: 27543252

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 24336783

Group type: EXPERIMENTAL
Intervention: Oral anticoagulation (OAC) treatment
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: OAC treatment in sinus rhythm (SR) subgroup
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Preoperative OAC use
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Other indications for OAC
Number of subjects: 115
Study: 21953589

Group type: EXPERIMENTAL
Intervention: Prednisolone 60 mg/day
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Prednisolone 30 mg/day
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 41
Study: 19585472

Group type: EXPERIMENTAL
Intervention: Purslane
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 18301121

Group type: EXPERIMENTAL
Intervention: Active treatments using the Sheehan Disability Scale (SDS)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Inactive treatments using the Sheehan Disability Scale (SDS)
Number of subjects: 37
Study: 15496867

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (MgSO4) >or=50 g
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Other tocolytic
Number of subjects: 140

Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 140
Study: 12618255

Group type: EXPERIMENTAL
Intervention: Manual Vacuum Aspiration (MVA)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Electric Vacuum Aspiration (EVA)
Number of subjects: 127
Study: 9474110

Group type: EXPERIMENTAL
Intervention: Home-based physical therapy (5 sessions)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Conventional physical therapy strategies incorporated into interactive play activities
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (continued center-based services)
Number of subjects: 38
Study: 7603607

Group type: EXPERIMENTAL
Intervention: 100 IU/day, continuously
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: 100 IU/day daily for 30 days every other month (cyclically)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: 200 IU/day, continuously
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: 200 IU/day, ciclically
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Cyclic and continuous treatment groups at the same dosage
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: 100 IU/day and 200 IU/day
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: S‐calcitonin therapy cessation
Number of subjects: 188
Study: 2743348

Group type: EXPERIMENTAL
Intervention: 400 mg trazodone daily
Number of subjects: 120

Group type: COMPARATOR
Intervention: 150 mg amitriptyline daily
Number of subjects: 120

Group type: COMPARATOR
Intervention: 20 mg haloperidol daily
Number of subjects: 120

Group type: COMPARATOR
Intervention: placebo daily
Number of subjects: 120
Study: 31876029

Group type: COMPARATOR
Intervention: Placebo drink (presumed energy drink)
Number of subjects: 20
Study: 29222993

Group type: EXPERIMENTAL
Intervention: GABA supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28412943

Group type: EXPERIMENTAL
Intervention: PaTH intervention group (n=163)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Usual care group (n=141)
Number of subjects: 304
Study: 26627507

Group type: EXPERIMENTAL
Intervention: Formative Assessment sessions (four sessions over one month)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Post-intervention summative assessment
Number of subjects: 68
Study: 22727979

Group type: EXPERIMENTAL
Intervention: Combined methods group A (all types of training)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Heavy-resistance group B (full-squat)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Power-oriented group C (parallel-squat)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ballistic group D (loaded countermovement jumping)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Plyometric group E
Number of subjects: 60
Study: 21174533

Group type: EXPERIMENTAL
Intervention: Bendamustine 120 mg/m² on days 1 and 2 of each 21-day cycle for six to eight cycles
Number of subjects: 0
Study: 19660462

Group type: EXPERIMENTAL
Intervention: Norfloxacin (400 mg/day)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Norfloxacin
Number of subjects: 31

Group type: COMPARATOR
Intervention: Trimethoprim/sulfamethoxazole
Number of subjects: 31
Study: 17134849

Group type: EXPERIMENTAL
Intervention: 400 mg L-dopa plus 100 mg carbidopa (Sinemet CR)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: 800 mg L-dopa plus 200 mg carbidopa (Sinemet CR)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 189
Study: 15170031

Group type: EXPERIMENTAL
Intervention: Endobronchial biopsy (EBB)
Number of subjects: 100
Study: 11581044

Group type: EXPERIMENTAL
Intervention: LASIK with Flapmaker microkeratome and Lasersight LSX excimer laser
Number of subjects: 13
Study: 9625838

Group type: EXPERIMENTAL
Intervention: Cancer genetic consultation
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Time since cancer diagnosis
Number of subjects: 115
Study: 7880610

Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion (c.i.v.) of recombinant human IL-2 (rIL-2)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Subcutaneous (s.c.) injections of recombinant human IL-2 (rIL-2)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Neutralising activity in patients with anti-rIL-2 antibodies
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Patients receiving at least two cycles of rIL-2 by s.c. injections
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Development of anti-rIL-2 antibodies
Number of subjects: 217
Study: 3709639

Group type: EXPERIMENTAL
Intervention: Indenolol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 12
Study: 29396245

Group type: EXPERIMENTAL
Intervention: Azathioprine (100-200 mg per day for 48 weeks)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Radiotherapy (20 Gy in 10-12 fractions over 2-3 weeks)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Sham radiotherapy and azathioprine (control group)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Sham radiotherapy and placebo (control group)
Number of subjects: 126
Study: 27472526

Group type: EXPERIMENTAL
Intervention: Mandibular advancement device (MAD)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 27
Study: 24858578

Group type: EXPERIMENTAL
Intervention: Psycho-echo-biofeedback (BFB), 4 sessions conducted by psychologists and a coloproctologist
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Psycho-echo-biofeedback (BFB)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (7 patients with normal bowel habits)
Number of subjects: 10
Study: 23145381

Group type: EXPERIMENTAL
Intervention: Divalproex extended release (ER)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 20230389

Group type: EXPERIMENTAL
Intervention: Docetaxel reintroduction as second-line therapy
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Docetaxel reintroduction
Number of subjects: 50
Study: 17894385

Group type: EXPERIMENTAL
Intervention: Alcohol beverage
Number of subjects: 328

Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 328
Study: 18083475

Group type: EXPERIMENTAL
Intervention: Percutaneous nonangiographic insertion of a venous access device
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard surgical cutdown insertion technique
Number of subjects: 100
Study: 14730657

Group type: EXPERIMENTAL
Intervention: Formoterol 4.5 microg b.i.d. for 12 weeks
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Formoterol 9 microg b.i.d. for 12 weeks
Number of subjects: 302

Group type: COMPARATOR
Intervention: Formoterol 4.5 microg and 9 microg
Number of subjects: 302
Study: 10972446

Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 8

Group type: COMPARATOR
Intervention: Nicotine cigarette
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo cigarette
Number of subjects: 8
Study: 9068935

Group type: EXPERIMENTAL
Intervention: Sertraline 50 mg/day titrated to 200 mg/day for 32 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 20
Study: 8415898

Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.5 mg, P.O.)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 3956820

Group type: EXPERIMENTAL
Intervention: Battery-operated iontophoretic device
Number of subjects: 27
Study: 30644599

Group type: EXPERIMENTAL
Intervention: 2-hour feeding interval
Number of subjects: 100

Group type: COMPARATOR
Intervention: 3-hour feeding interval
Number of subjects: 100
Study: 27443570

Group type: EXPERIMENTAL
Intervention: Integrated orthogeriatric treatment
Number of subjects: 850

Group type: COMPARATOR
Intervention: Standard care (historical control)
Number of subjects: 850
Study: 25577169

Group type: EXPERIMENTAL
Intervention: Open group (absence of closure)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Closed group (surgical wound closure)
Number of subjects: 54
Study: 23384428

Group type: EXPERIMENTAL
Intervention: Enzogenol (1000 mg/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 21356071

Group type: EXPERIMENTAL
Intervention: Singing group
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual activities (Control)
Number of subjects: 100
Study: 19481310

Group type: EXPERIMENTAL
Intervention: Low-fat (28% energy), high-complex carbohydrate diet with 1.24g/d LC n-3 PUFA (LFHCC n-3)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: High-fat (38% energy), MUFA-rich diet (HMUFA)
Number of subjects: 99

Group type: COMPARATOR
Intervention: High-fat (38% energy) SFA-rich diet (HSFA)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Low-fat (28% energy), high-complex carbohydrate diet (LFHCC)
Number of subjects: 99
Study: 16756402

Group type: EXPERIMENTAL
Intervention: VIPP (video-feedback and brochures to enhance sensitive parenting)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: VIPP-R (video-feedback, brochures, and discussions of mothers' childhood attachment experiences)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 81
Study: 15120547

Group type: EXPERIMENTAL
Intervention: Second-language speakers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Native speakers
Number of subjects: 0
Study: 12206016

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control
Number of subjects: 32
Study: 9303253

Group type: EXPERIMENTAL
Intervention: Cognitive therapy group program for headaches; two 90-minute sessions focusing on relaxation, distraction, visualization, and stress management skills.
Number of subjects: 36

Group type: COMPARATOR
Intervention: Waiting list control condition; treated 5 weeks later.
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Cognitive therapy group program for headaches; two 90-minute sessions.
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Follow-up ratings from parents after treatment.
Number of subjects: 36
Study: 8314199

Group type: EXPERIMENTAL
Intervention: Semilente (amorphous zinc insulin) injected at bedtime
Number of subjects: 10

Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 10
Study: 3084393

Group type: EXPERIMENTAL
Intervention: Comprehensive self-hypnosis training program (6-week duration)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Comprehensive self-hypnosis training program
Number of subjects: 30
Study: 31593133

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided transversus abdominis plane block (TAPB)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Patient-controlled intravenous analgesia (PCIA)
Number of subjects: 100
Study: 30044966

Group type: EXPERIMENTAL
Intervention: FLU + GAB
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: FLU + MEM
Number of subjects: 99

Group type: COMPARATOR
Intervention: FLU + PLA
Number of subjects: 99
Study: 27094506

Group type: EXPERIMENTAL
Intervention: Standard-dose (SD) group: 40 µg total vaccine dose, 20 µg at weeks 0 and 4
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: High-dose dose-intensive (HDDI) group: 80 µg total vaccine dose, 40 µg at weeks 0 and 4
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: High-dose time-intensive (HDTI) group: 80 µg total vaccine dose, 20 µg at weeks 0, 2, 4, and 6
Number of subjects: 114
Study: 25058879

Group type: EXPERIMENTAL
Intervention: PDP with ET‐Kyoto solution
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: PDP with cold storage/purification stock solution
Number of subjects: 18

Group type: COMPARATOR
Intervention: non‐PDP (control)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: PDP groups (both solutions)
Number of subjects: 18
Study: 21959688

Group type: EXPERIMENTAL
Intervention: TEP
Number of subjects: 100

Group type: COMPARATOR
Intervention: TAPP
Number of subjects: 100
Study: 20977760

Group type: EXPERIMENTAL
Intervention: Quantitative sensory testing (QST) in patients
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (30 subjects)
Number of subjects: 60
Study: 18375417

Group type: EXPERIMENTAL
Intervention: Self-weighing frequency (≥1/week)
Number of subjects: 5145

Group type: EXPERIMENTAL
Intervention: Eating breakfast
Number of subjects: 5145

Group type: EXPERIMENTAL
Intervention: Meals/snacks per day
Number of subjects: 5145

Group type: EXPERIMENTAL
Intervention: Fast food meals per week
Number of subjects: 5145

Group type: EXPERIMENTAL
Intervention: Weight control practices (increasing fruits and vegetables, cutting out sweets, eating less high-carbohydrate foods)
Number of subjects: 5145

Group type: COMPARATOR
Intervention: Self-weighing less than once per week
Number of subjects: 5145

Group type: COMPARATOR
Intervention: More fast food meals consumed per week
Number of subjects: 5145

Group type: COMPARATOR
Intervention: Fewer breakfast meals consumed per week
Number of subjects: 5145
Study: 15637746

Group type: EXPERIMENTAL
Intervention: Children with chronic constipation
Number of subjects: 70

Group type: COMPARATOR
Intervention: Healthy children (control group)
Number of subjects: 70
Study: 12789959

Group type: EXPERIMENTAL
Intervention: Light-curing (heat conversion) with 35% hydrogen peroxide
Number of subjects: 20

Group type: COMPARATOR
Intervention: No light-curing (no heat conversion) with 35% hydrogen peroxide
Number of subjects: 20
Study: 7618021

Group type: EXPERIMENTAL
Intervention: Active (temazepam)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 2650662

Group type: EXPERIMENTAL
Intervention: Clonidine hydrochloride (Catapres)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 21644

Group type: EXPERIMENTAL
Intervention: Melperone 100 mg X 3
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Thiothixene 10 mg X 3
Number of subjects: 63
Study: 31444140

Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 48

Group type: COMPARATOR
Intervention: Carvedilol
Number of subjects: 48
Study: 31334914

Group type: EXPERIMENTAL
Intervention: Renal denervation
Number of subjects: 17

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 17
Study: 29077819

Group type: EXPERIMENTAL
Intervention: RAPP (Recovery Assessment by Phone Points)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study: 26059463

Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg IV)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 23822135

Group type: EXPERIMENTAL
Intervention: Catheter ablation (CA) for long-standing persistent AF in women
Number of subjects: 220
Study: 21683412

Group type: EXPERIMENTAL
Intervention: Transobturator mid urethral sling
Number of subjects: 597

Group type: EXPERIMENTAL
Intervention: Retropubic mid urethral sling
Number of subjects: 597

Group type: EXPERIMENTAL
Intervention: Lowest quartile of Valsalva leak point pressure (<86 cm H2O)
Number of subjects: 597

Group type: EXPERIMENTAL
Intervention: Lowest quartile of maximum urethral closure pressure (<45 cm H2O)
Number of subjects: 597
Study: 19559297

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhammosus GG (minimum dose, 10 degrees bacteria)
Number of subjects: 229

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 229
Study: 16432349

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA) 500 mg intravenously before operation followed by 250 mg every 6 hours for 3 days
Number of subjects: 214

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 214
Study: 15514192

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (25 mg per day)
Number of subjects: 508

Group type: COMPARATOR
Intervention: Fosinopril (20 mg per day)
Number of subjects: 508

Group type: COMPARATOR
Intervention: Hydrochlorothiazide plus Pravastatin (40 mg per day)
Number of subjects: 508

Group type: COMPARATOR
Intervention: Fosinopril plus Pravastatin (40 mg per day)
Number of subjects: 508
Study: 11759560

Group type: EXPERIMENTAL
Intervention: 1% lidocaine injection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EMLA cream
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Numby Stuff
Number of subjects: 0
Study: 9548161

Group type: EXPERIMENTAL
Intervention: Triptorelin
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 7996343

Group type: EXPERIMENTAL
Intervention: modified Herbst appliance (mHA)
Number of subjects: 6

Group type: COMPARATOR
Intervention: muscle relaxation appliance (MR)
Number of subjects: 6
Study: 2663159

Group type: EXPERIMENTAL
Intervention: Ciclopirox olamine lotion 1%
Number of subjects: 89

Group type: COMPARATOR
Intervention: Vehicle alone
Number of subjects: 89
Study: 31216215

Group type: EXPERIMENTAL
Intervention: Ketorolac (10-mg tablets every 8 h)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Gabapentin (300-mg capsules every 8 h)
Number of subjects: 37
Study: 30016518

Group type: EXPERIMENTAL
Intervention: Intervention regions (Healthy Together Victoria)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Comparison regions (non-intervention)
Number of subjects: 107
Study: 26946615

Group type: EXPERIMENTAL
Intervention: Bloodletting therapy at local myofascial trigger points and acupuncture at Jiaji (EX-B 2) points
Number of subjects: 66

Group type: COMPARATOR
Intervention: Lidocaine block therapy
Number of subjects: 66
Study: 22462436

Group type: EXPERIMENTAL
Intervention: SMS-RUTF
Number of subjects: 45

Group type: COMPARATOR
Intervention: P-RUTF
Number of subjects: 45
Study: 23167854

Group type: EXPERIMENTAL
Intervention: Mechanical Resuscitation Device (MRD)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard Basic Life Support (BLS)
Number of subjects: 80
Study: 21123501

Group type: EXPERIMENTAL
Intervention: Reflective blogging
Number of subjects: 58
Study: 17645494

Group type: EXPERIMENTAL
Intervention: Nei-Guan point acupressure
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control (conventional intravenous treatment)
Number of subjects: 66
Study: 15702859

Group type: EXPERIMENTAL
Intervention: L. plantarum 299v in an oatmeal-fermented drink (10(9) CFU/ml) given twice daily
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 11790498

Group type: EXPERIMENTAL
Intervention: 99mTc‐labelled lactose inhaled at four inspiratory flows (30, 40, 60, and 80 l/min)
Number of subjects: 8